Psoriatic Arthritis Treatment Industry Growth Expected to Reach $17.16 Billion by 2029 at a CAGR of 9.4% | Segmentation and Growth Opportunities
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
#How Has the Psoriatic Arthritis Treatment Market Growth Performance Trended Historically, And What Lies Ahead?
In recent times, the psoriatic arthritis treatment market has experienced significant growth. The market size, which stood at $10.93 billion in 2024, is projected to increase to $12 billion in 2025, at a compound annual growth rate (CAGR) of 9.8%. Factors such as improved diagnostics, a rising occurrence of psoriatic arthritis, enhanced awareness regarding the disease and its remedies, an increased selection of approved treatments, government backing for R&D, and amplified funding from pharmaceutical firms, contributed to the growth experienced during the historical period.
What Is the Forecast for the Psoriatic Arthritis Treatment Market Size Through 2029?
The market for the treatment of psoriatic arthritis is projected to experience significant expansion in the forthcoming years, reaching a value of $17.16 billion by 2029, with a Compound Annual Growth Rate (CAGR) of 9.4%. The surge in growth forecasted for this period is due to factors such as the rise of personalized medicine, the development of biologics and small molecules, increased variety in treatment options, and a globally aging population. Key future trends to track include progress in biologics, oral small molecules, pathway-specific targeting, telemedicine coupled with remote monitoring, patient-oriented care, and the use of real-world evidence.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3458&type=smp
What are the Key Market Players in Psoriatic Arthritis Treatment Market and How They’re Evolving?
Major companies operating in the psoriatic arthritis treatment market include AbbVie Inc., Amgen Astellas BioPharma K.K., Johnson & Johnson Services Inc., Bristol-Myers Squibb Company, Celgene Corporation, Novartis International AG, Eli Lilly and Company, Pfizer Inc., CB Biosciences Inc., Merck & Co. Inc., AstraZeneca plc, Sanofi SA, Otsuka Pharmaceutical Co. Ltd., Sumitomo Dainippon Pharma Co. Ltd., Bayer AG, Abbott Laboratories, Eisai Inc., Janssen Pharmaceuticals Inc., Bausch Health Companies Inc., F. Hoffmann-La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline plc, LEO Pharma A/S, Regeneron Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Valeant Pharmaceuticals International Inc., Chugai Pharmaceutical Co. Ltd., Kyowa Kirin Co. Ltd.
What Are the Primary Growth Drivers in the Psoriatic Arthritis Treatment Market?
Inflammatory disorders like psoriasis and psoriatic arthritis have seen a surge in prevalence lately, which in turn has fueled the growth of the psoriatic arthritis treatment market. Psoriasis, which often coexists with an inflammatory type of arthritis referred to as psoriatic arthritis (PsA), affects 30% of those with psoriasis. As per the data released by the National Library of Medicine, a US-government agency, in January 2024, the yearly incidence of PsA among psoriasis patients fluctuates between 1.9% and 2.7% per 100 patients. The probability of developing PsA shows a notable rise over time, with rates standing at 1.7% after 5 years, escalating to 3.1% after 10 years, and skyrocketing to 20.5% 30 years post a psoriasis diagnosis. Therefore, the escalating prevalence of both psoriasis and psoriatic arthritis is a key factor propelling market growth.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=3458&type=smp
What Are the Leading Segments in the Global Psoriatic Arthritis Treatment Industry?
The psoriatic arthritis treatment market covered in this report is segmented –
1) By Drug Class: Nonsteroidal Anti-Inflammatory Drugs (NSAIDS), Disease-Modifying Anti-Rheumatic Drugs (DMARDS), Biologics, Other Drug Classes
2) By Route Of Administration: Oral, Parenteral, Topical
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): Traditional NSAIDs, COX-2 Inhibitors
2) By Disease-Modifying Anti-Rheumatic Drugs (DMARDs): Conventional DMARDs, Targeted Synthetic DMARDs
3) By Biologics: Tumor Necrosis Factor (TNF) Inhibitors, Interleukin Inhibitors, Other Biologics
4) By Other Drug Classes: Corticosteroids, Topical Treatments, Janus Kinase (JAK) Inhibitors
What Are the Key Market Trends in the Psoriatic Arthritis Treatment Industry?
Significant organizations in the psoriatic arthritis treatment market are constantly making strides towards developing advanced solutions like targeted biologic therapy. This development is focused on offering more efficient and personalized treatment alternatives that tackle the root inflammatory issues, elevate patient results and improve the general life quality of those dealing with this persistent ailment. Targeted biologic therapy employs specifically formulated drugs or substances to interact with particular molecules that drive the growth and proliferation of cancer cells. The primary aim is to reduce harm to healthy cells while augmenting therapeutic effectiveness. An illustration of this is when AbbVie, a biopharmaceutical firm based in the US, announced the approval of SKYRIZI (risankizumab-rzaa) by the U.S. Food and Drug Administration (FDA) in January 2022. SKYRIZI® (risankizumab-rzaa) is an interleukin-23 inhibitor that is exclusively used for active psoriatic arthritis treatment. It targets the inflammation source by hindering the p19 component of IL-23. Clinical trials have shown significant enhancements in joint symptoms and overall disease activity, resulting in numerous patients attaining clinical remission and an improved life quality. The therapy can be delivered through a subcutaneous injection, offering a controllable choice for patients and accommodating adjustable dosage schedules as per individual requirements.
Access The Full Report Here:
What Is the Regional Outlook for the Psoriatic Arthritis Treatment Market?
The countries covered in the psoriatic arthritis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3458
This Report Delivers Insight On:
1. How big is the psoriatic arthritis treatment market, and how is it changing globally?
2. Who are the major companies in the psoriatic arthritis treatment market, and how are they performing?
3. What are the key opportunities and risks in the psoriatic arthritis treatment market right now?
4. Which products or customer segments are growing the most in the psoriatic arthritis treatment market?
5. What factors are helping or slowing down the growth of the psoriatic arthritis treatment market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 2071930708
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
